We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Neurofilament Subunit L Levels in the Cerebrospinal Fluid and Serum of Patients with Amyotrophic Lateral Sclerosis.
- Authors
Gong, Zhong-Ying; Lv, Gao-Peng; Gao, Li-Na; Lu, Yi; Guo, Jie; Zang, Da-Wei
- Abstract
<bold>Background:</bold> There are no reliable biomarkers that could evaluate the disease burden in amyotrophic lateral sclerosis (ALS). <bold>Objectives:</bold> The aim of our study is to evaluate the changes in cerebrospinal fluid (CSF) and serum neurofilament subunit L (NF-L) in patients with ALS and to analyze the correlations between the levels of NF-L and clinical parameters. <bold>Method:</bold> CSF and serum samples were obtained from 80 ALS patients and 40 controls. The levels of NF-L in CSF and serum were assessed, and disease progression parameters including duration, revised ALS Functional Rating Scale (ALSFRS-r) score, disease progression rate (DPR), upper motor neuron (UMN) score, and survival were analyzed by registered neurologists. All samples were measured using a commercial enzyme-linked immunosorbent assay. Statistical analyses were performed using Prism software. <bold>Results:</bold> Compared to the controls, the ALS patients displayed significantly increased levels of NF-L; these values were negatively correlated with the ALSFRS-r score and positively correlated with the decrease in ALSFRS-r score, DPR, and UMN score. There was no correlation between levels of NF-L and duration. In addition, the cumulative survival rate in ALS patients with a low level of NF-L was higher than in patients with a high level of NF-L. <bold>Conclusions:</bold> NF-L levels increased in CSF and serum of patients with ALS. NF-L may thus be a neurodegenerative biomarker for predicting ALS severity and progression, and the survival of patients with this disease.
- Subjects
AMYOTROPHIC lateral sclerosis; CEREBROSPINAL fluid examination; CYTOPLASMIC filaments; BLOOD serum analysis; DISEASE progression; DISEASE duration; SURVIVAL; ENZYME-linked immunosorbent assay; PATIENTS
- Publication
Neurodegenerative Diseases, 2018, Vol 18, Issue 2/3, p165
- ISSN
1660-2854
- Publication type
Article
- DOI
10.1159/000488681